Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
Categories: News

Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors

NEWTON, Mass.–(BUSINESS WIRE)–Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors. Dr. Pruzanski brings more than 30 years of experience as a life sciences executive, entrepreneur and investor.


“We are thrilled to welcome Mark as the Chairman of the Board during a pivotal stage for Abcuro as we continue to advance our registrational Phase 2/3 MUSCLE clinical study for the treatment of inclusion body myositis,” said Alex Martin, Chief Executive Officer of Abcuro. “Mark is a biotech leader with a proven record in bringing innovative new medicines to market for patient populations with unmet medical needs. His operational and financial expertise will be invaluable as we continue developing ulviprubart (ABC008) and expand our therapeutic pipeline.”

“I am excited to join Abcuro’s Board at this important time in the Company’s life cycle,” said Dr. Pruzanski. “I look forward to partnering and working closely with this talented Board and management team to help ensure the success of their leading programs addressing diseases for which there are few, if any, treatment options available.”

Until its recent acquisition by Eli Lilly and Company, Dr. Pruzanski served as the Chairman and Chief Executive Officer of Versanis Bio, focused on the development of new medicines for the treatment of obesity and other cardiometabolic diseases. Prior to joining Versanis, Dr. Pruzanski founded Intercept Pharmaceuticals and was the company’s Chief Executive Officer until 2021, having led its evolution from drug discovery stage to a global development and commercial organization. While at Intercept, he pioneered novel surrogate endpoints supporting accelerated approval in chronic liver diseases, gaining multiple regulatory approvals for the autoimmune disease PBC and championing the development of therapeutics for NASH.

Dr. Pruzanski is an active board member for several biotechnology companies and healthcare organizations, including the Emerging Company Section of the Biotechnology Innovation Organization (BIO). Earlier in his career, he worked in life sciences investment and venture capital, having co-founded Apple Tree Partners. Dr. Pruzanski earned his M.D. from McMaster University Medical School and his M.A. in International Affairs from John Hopkins University.

About Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia. For more information, visit us on LinkedIn and at abcuro.com.

Contacts

Matthew DeYoung

Investor Relations and Media

Argot Partners

abcuro@argotpartners.com

Staff

Recent Posts

A New Era in Precision Medicine: SimBioSys Announces Strategic Collaboration with Magic Leap to Advance TumorSight Platform with AR Integration

SimBioSys and Magic Leap join forces to integrate AI-powered TumorSight Viz with AR technology, revolutionizing…

1 hour ago

New AI-Powered Offering from NPG Unlocks Community Intelligence For Tech-Centered Brands

CLAIR, Co-developed by NPG Firms 104 West and Ringer Sciences, Extracts Insights from Places Where…

1 hour ago

Gopuff Unveils Powered by Gopuff, a New Platform Enabling Brands to Fulfill Instant Delivery From Their eCommerce Websites

Powered by Gopuff debuts with more than 20 leading CPG partners leveraging the platform to…

2 hours ago

The Knot Partners With Shondaland and Netflix’s Bridgerton to Launch an Exclusive Collection of Modern Regency Wedding Stationery

The Bridgerton x The Knot collection offers couples modern Regency-inspired stationery for their wedding celebration,…

2 hours ago

Brightcove Introduces Smart TV SDKs for Roku, Samsung, and LG Devices, Empowering Media Companies to Reach New Audiences

The new SDKs streamline the development and management of native apps for premium OTT and…

2 hours ago

Worldwide Smartphone Market Up 7.8% in the First Quarter of 2024 as Samsung Moves Back into the Top Position, According to IDC Tracker

NEEDHAM, Mass.--(BUSINESS WIRE)--#Apple--According to preliminary data from the International Data Corporation (IDC) Worldwide Quarterly Mobile…

2 hours ago